Understanding the role of DNMT1 SUMOylation in Acute Myeloid Leukaemia [ 1/1/2021 - 12/31/2023 ]

Research Grant

Brief description Most cancers have abnormally high levels of DNA methylation, which turns off cell death genes, making cancer cells immortal. We have a new drug, called DNMT1i, that targets this feature of cancer cells and we recently found a new drug target that enhances the activity of DNMT1i. Our research will determine how these two drugs synergise to effectively kill cancer cells and will justify their use in clinical trials, which we believe will improve outcomes for patients with cancer.

Funding Amount $639,290

Funding Scheme Ideas Grants

Chief Investigator Dr Brian Liddicoat

Notes Ideas Grants